

WntResearch to present on the 11th Annual Biotech in Europe Investor Forum arranged by Sachs Forum in Zürich and at investor meetings arranged by Aktiespararna in Umeå and Örebro

WntResearch AB (publ) has been invited to present at the 11th Annual Biotech in Europe Investor Forum, September 13-14 in Zürich, arranged by Sachs Forum. The Company will also present its current activities at two meetings in Sweden in Umeå, September 21st, and in Örebro on September 28. For participation please contact Aktiespararna.

CEO Bert Junno comments:

"I am happy that WntResearch as a company is of such general interest that we get invited to international investor conferences such as the Sachs Forum. It is important for the company to be active in business development activities and to keep good relations with pharmaceutical companies and professional investors. It is of equal importance that the management of the Company meets with investors in Sweden to present WntResearch and to answer questions from shareholders. More investor meetings will take place later in the fall and will be announced later."

For more information contact:

Bert Junno, CEO
WntResearch AB (publ)

Tel: +46-707-772209

E-mail: bert.junno@wntresearch.com

About WntResearch AB

WntResearch (WNT.ST) is a public company listed at the AktieTorget and is a research based Biotech Company spun out of Lund University, Sweden, founded in 2007. The focus and aim of WntResearch is to develop novel anti-metastatic therapies, in areas of unmet need, for the treatment of cancer patients. The company has two major drug development projects, Foxy-5 and Box-5. The lead project Foxy-5 is currently being tested in in-vivo models and is planned to enter phase 1 clinical trials in metastatic cancer in 2012.